VIGNALI Laboratory

Are Regulatory T cells Defective in Type 1 Diabetes and Can We Fix Them?

Visperas A, Vignali DAA.

Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.

Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin JH, Kang HC, Zhang J, Xu J, Chen R, Park H, Andrabi SA, Kang SU, Gonçalves RA, Liang Y, Zhang S, Qi C, Lam S, Keiler JA, Tyson J, Kim D, Panicker N, Yun SP, Workman CJ, Vignali DA, Dawson VL, Ko HS, Dawson TM.

Binding of the cytoplasmic domain of CD28 to the plasma membrane inhibits Lck recruitment and signaling.

Dobbins J, Gagnon E, Godec J, Pyrdol J, Vignali DA, Sharpe AH, Wucherpfennig KW.

Targeting regulatory T cells in tumors.

Liu C, Workman CJ, Vignali DA.

Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Zhang Q, Vignali DA.

Kinetics of Alloantigen-Specific Regulatory CD4 T Cell Development and Tissue Distribution After Donor-Specific Transfusion and Costimulatory Blockade.

Tomita Y, Satomi M, Bracamonte-Baran W, Jankowska Gan E, Workman AS, Workman CJ, Vignali DA, Burlingham WJ.

T(reg) stability: to be or not to be.

Overacre AE, Vignali DA.

Interleukin-35 Limits Anti-Tumor Immunity.

Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ, Vignali DA.

Mucosal Administration of Collagen V Ameliorates the Atherosclerotic Plaque Burden by Inducing Interleukin 35-dependent Tolerance.

Park AC, Huang G, Jankowska-Gan E, Massoudi D, Kernien JF, Vignali DA, Sullivan JA, Wilkes DS, Burlingham WJ, Greenspan DS.

An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy.

Do JS, Visperas A, Sanogo YO, Bechtel JJ, Dvorina N, Kim S, Jang E, Stohlman SA, Shen B, Fairchild RL, Baldwin WM III, Vignali DA, Min B.